var data={"title":"Dexamethasone (systemic): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Dexamethasone (systemic): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/388152?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=dexamethasone-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Dexamethasone (systemic): Patient drug information \t&quot;</a> and <a href=\"topic.htm?path=dexamethasone-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Dexamethasone (systemic): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015648\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Active Injection D;</li>\n      <li>Baycadron [DSC];</li>\n      <li>Decadron;</li>\n      <li>Dexamethasone Intensol;</li>\n      <li>DexPak 10 Day;</li>\n      <li>DexPak 13 Day;</li>\n      <li>DexPak 6 Day;</li>\n      <li>DoubleDex;</li>\n      <li>LoCort 11-Day;</li>\n      <li>LoCort 7-Day;</li>\n      <li>MAS Care-Pak;</li>\n      <li>ReadySharp Dexamethasone;</li>\n      <li>TaperDex 12-Day;</li>\n      <li>TaperDex 6-Day;</li>\n      <li>Zodex 12-Day [DSC];</li>\n      <li>Zodex 6-Day [DSC];</li>\n      <li>ZonaCort 11 Day;</li>\n      <li>ZonaCort 7 Day</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015649\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Dexasone</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8016759\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Anti-inflammatory Agent;</li>\n      <li>\n        Antiemetic;</li>\n      <li>\n        Corticosteroid, Systemic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015752\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Adrenal crisis (shock due to adrenal insufficiency and unresponsive to conventional therapy) (off-label dose):</b> IV: 4 to 10 mg as a single dose, which may be repeated if necessary. <b>Note:</b> Hydrocortisone is the preferred agent in this setting (ES [Bornstein 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anti-inflammatory/immunosuppressive/endocrine disorders:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral, IM, IV: 0.5 to 9 mg/day in divided doses every 6 to 12 hours; dose depends upon condition being treated and response of patient.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intra-articular, intralesional, or soft tissue injection: Dosage and frequency depend on the condition and the site of injection; frequency range: once every 3 to 5 days to once every 2 to 3 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Large joints (eg, knee): Single dose: 2 to 4 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Small joints (eg, interphalangeal, temporomandibular): Single dose: 0.8 to 1 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Bursae: Single dose: 2 to 4 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Tendon Sheaths: Single dose: 0.4 to 1 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Soft tissue infiltration: Single dose: 2 to 6 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Ganglia: 1 to 2 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Brain tumor (palliative management of cerebral edema or neurological deficits associated with recurrent or inoperable brain tumors): </b>Oral, IV: 2 mg 2 to 3 times daily may be effective; individualize dose based on disease response and patient tolerance.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cerebral edema (associated with brain tumor or craniotomy):</b> IM, IV: 10 mg IV immediately, followed by 4 mg IM every 6 hours until cerebral edema subsides, then switch to oral regimen; dosage may be reduced after 2 to 4 days and gradually discontinued over 5 to 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cushing syndrome, diagnostic (low dose):</b> Oral: 1 mg at 11 PM, draw blood at 8 AM; greater accuracy for Cushing syndrome may be achieved with 0.5 mg every 6 hours for 48 hours (with 24-hour urine collection for 17-hydroxycorticosteroid excretion)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Differentiation of Cushing syndrome due to ACTH excess from Cushing due to other causes:</i> Oral: 2 mg every 6 hours for 48 hours (with 24-hour urine collection for 17-hydroxycorticosteroid excretion)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Immune thrombocytopenia (primary), initial therapy:</b> Oral: 40 mg once daily for 4 consecutive days; if platelet count continues to remain &lt;30,000/mm<sup>3</sup> or bleeding symptoms occur by day 10, may administer an additional 4-day course of 40 mg once daily (Wei 2016) <b>or</b> 40 mg once daily for 4 consecutive days, if platelets fall below 30,000/mm<sup>3</sup> within 6 months a second course may be administered, followed by a prednisone taper (Cheng 2003). Pulsed dexamethasone dosing of 40 mg once daily for 4 days every 14 or 28 days for 4 to 6 cycles has also been used (Mazzucconi 2007; Provan 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Multiple sclerosis (acute exacerbation):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Treatment guidelines recommend the use of high dose IV or oral methylprednisolone for acute exacerbations of multiple sclerosis (AAN [Scott 2011], NICE 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 30 mg/day for 1 week, followed by 4 to 12 mg every other day for 1 month</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute mountain sickness (AMS)/high altitude cerebral edema (HACE) (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Prevention:</i></b> Oral: 2 mg every 6 hours <b>or</b> 4 mg every 12 hours starting on the day of ascent; may be discontinued after staying at the same elevation for 2 to 3 days or if descent is initiated; do not exceed a 10 day duration (Luks 2010). <b>Note:</b> In situations of rapid ascent to altitudes &gt;3500 meters (such as rescue or military operations), 4 mg every 6 hours may be considered (Luks 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Treatment:</i></b> Oral, IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>AMS:</i> 4 mg every 6 hours (Luks 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>HACE:</i> Initial: 8 mg as a single dose; Maintenance: 4 mg every 6 hours until symptoms resolve (Luks 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Accelerated fetal lung maturation (off-label use):</b> IM: 6 mg every 12 hours for a total of 4 doses (ACOG 171 2016). A single course is recommended for women between 24 and 34 weeks of gestation, including those with ruptured membranes or multiple gestations, who are at risk of delivering within 7 days. A single course may be appropriate in some women beginning at 23 weeks gestation or late preterm (between 34 0/7 weeks and 36 6/7 weeks gestation). A single repeat course may be considered in some women with pregnancies less than 34 weeks gestation at risk for delivery within 7 days and who had a course of antenatal corticosteroids &gt;14 days prior (ACOG 171 2016; ACOG 172 2016; ACOG 677 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Airway edema or extubation (off-label use):</b> IV: 0.5 mg/kg/dose (maximum dose: 10 mg/dose) 6 to 12 hours prior to extubation then every 6 hours for 5 doses (Khemani 2009) <b>or</b> 5 mg every 6 hours for 4 doses with extubation performed 24 hours after last injection (Lee 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chemotherapy-associated nausea and vomiting, prevention (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Highly emetic chemotherapy (in combination with an NK<sub>1</sub> receptor antagonist, a 5-HT<sub>3</sub> antagonist, and olanzapine; </i>\n      <i>dexamethasone dose depends on specific NK<sub>1</sub> receptor antagonist [Hesketh 2017; Roila 2016])</i>: Oral or IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">In combination with oral aprepitant, or netupitant-palonosetron: 12 mg on day 1, followed by 8 mg once daily on days 2 to 4</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">In combination with IV fosaprepitant: 12 mg on day 1, followed by 8 mg on day 2, and 8 mg twice daily on days 3 and 4</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">In combination with rolapitant: 20 mg on day 1, followed by 8 mg twice daily on days 2 to 4</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If NK<sub>1</sub> receptor antagonist not used: 20 mg day 1, followed by 8 mg twice daily on days 2 to 4</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>High emetic potential anthracycline/cyclophosphamide chemotherapy:</i> Oral, IV: 12 mg with aprepitant, fosaprepitant, or netupitant/palonosetron <b>or </b>20 mg with rolapitant; in combination with a 5HT<sub>3</sub> antagonist on day 1 and olanzapine on days 1 to 4 (Hesketh 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Moderate emetic potential chemotherapy:</i> Oral, IV: 8 mg on day 1 prior to chemotherapy (in combination with a 5HT<sub>3</sub> antagonist on day 1) and 8 mg on days 2 and 3; may be administered as 4 mg twice daily (Hesketh 2017; Roila 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Low emetic potential chemotherapy:</i> Oral, IV: 4 to 8 mg prior to chemotherapy (Hesketh 2017; Roila 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dosing when used in combination with extended-release granisetron (Raftopoulos 2015):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Day 1: IV: 20 mg (for highly emetic chemotherapy) <b>or</b> 8 mg (for moderately emetic chemotherapy)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Days 2, 3, and 4: Oral: 8 mg twice daily (for highly emetic chemotherapy)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dosing when used in combination with IV aprepitant (and a 5HT<sub>3</sub> antagonist):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Highly emetic chemotherapy</i>: Oral: 12 mg on day 1, followed by 8 mg on day 2 and then 8 mg twice daily on days 3 and 4</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Moderately emetic chemotherapy</i>: Oral: 12 mg on day 1 only</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dexamethasone suppression test (depression/suicide indicator) (off-label use):</b> Oral: 1 mg at 11 PM, draw blood at 8 AM the following day for plasma cortisol determination</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Glucocorticoid remediable aldosteronism, treatment (off-label use): </b>Oral: Initial: 0.125 to 0.25 mg once daily, preferably at bedtime to suppress early morning ACTH surge (Funder 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Multiple myeloma (off-label use): </b> <b>Note:</b> Multiple dexamethasone-containing regimens are available for the treatment of multiple myeloma. Refer to appropriate literature/guidelines for additional details.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 40 mg once daily on days 1 to 4, 9 to 12, and 17 to 20 (as induction therapy) in combination with bortezomib and doxorubicin for 3 cycles (Sonneveld 2012) <b>or</b> 40 mg once weekly on days 1, 8, 15, and 22 every 28 days (in combination with lenalidomide) until disease progression (Rajkumar 2010) or 40 mg once weekly on days 1, 8, 15, and 22 every 28 days (in combination with pomalidomide) until disease progression or unacceptable toxicity (San Miguel 2013) <b>or</b> 40 mg once weekly on days 1, 8, 15, and 22 every 28 days (in combination with ixazomib and lenalidomide) until disease progression or unacceptable toxicity (Moreau 2015) <b>or</b> 28 mg orally plus 8 mg IV (prior to elotuzumab) on days 1, 8, 15, and 22 every 28 days for 2 cycles, followed by 28 mg orally plus 8 mg IV (prior to elotuzumab) on days 1 and 15 and 40 mg orally on days 8 and 22 every 28 days thereafter until disease progression or unacceptable toxicity (in combination with elotuzumab and lenalidomide) (Lonial 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral or IV: 20 mg once daily days 1, 2, 4, 5, 8, 9, 11, and 12 every 21 days (in combination with daratumumab and bortezomib) for 8 cycles (Palumbo 2016) <b>or</b> 20 mg on days 1 (prior to daratumumab infusion) and 2 each week (in combination with daratumumab and lenalidomide) until disease progression or unacceptable toxicity (Dimopoulos 2016a); for patients &gt;75 years of age, BMI &lt;18.5, poorly controlled diabetes, or corticosteroid intolerance a reduced dexamethasone dose of 20 mg once a week was used (Dimopoulos 2016a; Palumbo 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015751\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=dexamethasone-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Dexamethasone (systemic): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anti-inflammatory/immunosuppressive/endocrine disorders:</b> Infants, Children, and Adolescents: Oral, IM, IV: Initial dose range: 0.02 to 0.3 mg/kg/<b>day</b> (0.6 to 9 mg/m<sup>2</sup>/<b>day</b>) in divided doses every 6 to 12 hours; dose depends upon condition being treated and response of patient; dosage for infants and children should be based on disease severity and patient response</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Asthma exacerbation:</b> Limited data available: Infants, Children, and Adolescents: Oral, IM, IV: 0.6 mg/kg once daily as a single dose or once daily for 2 days; maximum dose: 16 mg/dose (Hegenbarth 2008; Keeney 2014; Qureshi 2001); single dose regimens as low as 0.3 mg/kg/dose and as high as 1.7 mg/kg/dose have also been reported (Keeney 2014; Qureshi 2001; Shefrin 2009). <b>Note: </b>Duration greater than 2 days is not recommended due to increased risk of metabolic effects (GINA 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cerebral edema: </b>Infants, Children, and Adolescents: Oral, IM, IV: Loading dose: 1 to 2 mg/kg/dose as a single dose; maintenance: 1 to 1.5 mg/kg/<b>day</b> in divided doses every 4 to 6 hours; maximum: 16 mg/<b>day</b> (Kleigman 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Congenital adrenal hyperplasia:</b> Adolescents (fully grown): Oral: 0.25 to 0.5 mg once daily (AAP 2010; Speiser 2010). <b>Note:</b> For younger patients who are still growing, hydrocortisone or fludrocortisone are preferred.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Physiologic replacement:</b> Infants, Children, and Adolescents: Oral, IM, IV: 0.03 to 0.15 mg/kg/<b>day</b> in divided doses every 6 to 12 hours (Kleigman 2007) or 0.2 to 0.25 mg/m<sup>2</sup>/<b>day</b> once daily; some patients may require 0.3 mg/m<sup>2</sup>/<b>day</b> (Gupta 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute mountain sickness (AMS) (moderate)/high altitude cerebral edema (HACE) (off-label use):</b> Limited data available: Infants, Children, and Adolescents: Oral, IM, IV: 0.15 mg/kg/dose every 6 hours; maximum dose: 4 mg/dose; consider using for high altitude pulmonary edema because of associated HACE with this condition (Luks 2010; Pollard 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Airway edema or extubation (off-label use): </b> Limited data available: Infants, Children, and Adolescents: IV: 0.5 mg/kg/dose (maximum dose: 10 mg/dose) 6 to 12 hours prior to extubation then every 6 hours for 5 doses (total dexamethasone dose: 3 mg/kg) (Anene 1996; Khemani 2009; Tellez 1991)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bacterial meningitis (</b>\n      <b>\n        <i>H. influenzae</i></b> <b>type b) (off-label use):</b> Limited data available: Infants &gt;6 weeks and Children: IV: 0.15 mg/kg/dose every 6 hours for the first 2 to 4 days of antibiotic treatment; start dexamethasone 10 to 20 minutes before or with the first dose of antibiotic; if antibiotics have already been administered, dexamethasone use has not been shown to improve patient outcome and is not recommended (Tunkel 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chemotherapy-associated nausea and vomiting, prevention (off-label use):</b> Pediatric Oncology Group of Ontario guideline recommendations (Dupuis 2013): Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>High emetic potential chemotherapy:</i> Oral, IV: 6 mg/m<sup>2</sup>/dose every 6 hours (in combination with a 5HT<sub>3</sub> antagonist and aprepitant [if no interaction with aprepitant and if &ge;12 years]); reduce dexamethasone dose by 50% if administered concomitantly with aprepitant</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Moderate emetic potential chemotherapy:</i> Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">BSA &le;0.6 m<sup>2</sup>: 2 mg every 12 hours (in combination with a 5HT<sub>3</sub> antagonist)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">BSA &gt;0.6 m<sup>2</sup>: 4 mg every 12 hours (in combination with a 5HT<sub>3</sub> antagonist)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Croup (laryngotracheobronchitis) (off-label use):</b> Limited data available: Infants and Children: Oral, IM, IV: 0.6 mg/kg once; usual maximum dose: 16 mg (doses as high as 20 mg have been used) (Bjornson 2004; Hegenbarth 2008; Rittichier 2000). <b>Note:</b> a single oral dose of 0.15 mg/kg has been shown effective in children with mild to moderate croup (Russell 2004; Sparrow 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Immune thrombocytopenia (primary), second-line treatment (off-label use):</b> Children and Adolescents: Oral: 0.6 mg/kg/<b>day</b> for 4 days every 4 weeks up to 6 cycles (Neunert 2011). Consider a maximum daily dose cap (eg, 24 mg or 40 mg) based on response, individual tolerance and/or institutional policy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Immune thrombocytopenia, chronic (refractory) (off-label use):</b> Children and Adolescents: Oral: 0.6 mg/kg/<b>day</b> for 4 days every 4 weeks for 6 cycles (Hedlund-Treutiger 2003; Neunert 2011) <b>or</b> 28 to 40 mg/m<sup>2</sup>/<b>day</b> for 4 days every 4 weeks for 6 cycles (response usually observed within 3 days); maximum dose: 40 mg/<b>day</b> (Chen 1997; Khune 1997; Provan 2010]). Consider a maximum daily dose cap (eg, 24 mg or 40 mg) based on response, individual tolerance and/or institutional policy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015753\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Use cautiously in the elderly in the smallest possible dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015754\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: Supplemental dose is not necessary (Aronoff 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peritoneal dialysis: Supplemental dose is not necessary (Aronoff 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>International Myeloma Working Group (IMWG) Recommendations:</i> The International Myeloma Working Group (IMWG) recommendations suggest that dexamethasone may be administered without dosage adjustment in multiple myeloma patients with renal impairment, including those on dialysis. The IMWG recommends the use of the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (preferred) or the Modification of Diet in Renal Disease (MDRD) formula to evaluate renal function estimation in multiple myeloma patients with a stable serum creatinine (Dimopoulos 2016b).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15827036\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8016329\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Concentrate, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dexamethasone Intensol: 1 mg/mL (30 mL) [contains alcohol, usp; unflavored flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Elixir, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Baycadron: 0.5 mg/5 mL (237 mL [DSC]) [contains alcohol, usp, benzoic acid, fd&amp;c red #40, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.5 mg/5 mL (237 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Injection, as sodium phosphate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ReadySharp Dexamethasone: 10 mg/mL [contains benzyl alcohol, sodium sulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Injection, as sodium phosphate [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Active Injection D: 10 mg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">DoubleDex: 10 mg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">MAS Care-Pak: 10 mg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.5 mg/5 mL (240 mL, 500 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as sodium phosphate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 mg/mL (1 mL); 20 mg/5 mL (5 mL); 120 mg/30 mL (30 mL); 10 mg/mL (1 mL); 100 mg/10 mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as sodium phosphate [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 mg/mL (1 mL); 10 mg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as sodium phosphate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/50 mL in NaCl 0.9% (50 mL); 12 mg/50 mL in NaCl 0.9% (50 mL); 20 mg/50 mL in NaCl 0.9% (50 mL); 8 mg/50 mL in NaCl 0.9% (50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Intravenous, as sodium phosphate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/2.5 mL (2.5 mL); 12 mg/3 mL (3 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Decadron: 0.5 mg [scored; contains fd&amp;c yellow #10 (quinoline yellow), tartrazine (fd&amp;c yellow #5)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Decadron: 0.75 mg [scored; contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Decadron: 4 mg, 6 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">DexPak 10 Day: 1.5 mg [scored; contains fd&amp;c red #40 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">DexPak 13 Day: 1.5 mg [scored; contains fd&amp;c red #40 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.5 mg, 0.75 mg, 1 mg, 1.5 mg, 2 mg, 4 mg, 6 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Therapy Pack, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">DexPak 6 Day: 1.5 mg (21 ea) [scored; contains fd&amp;c red #40 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LoCort 11-Day: 1.5 mg (41 ea) [scored; contains fd&amp;c red #40]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LoCort 7-Day: 1.5 mg (27 ea) [scored; contains fd&amp;c red #40]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">TaperDex 12-Day: 1.5 mg (49 ea) [contains fd&amp;c red #40]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">TaperDex 6-Day: 1.5 mg (21 ea) [contains fd&amp;c red #40 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zodex 12-Day: 1.5 mg (49 ea [DSC]) [scored; contains fd&amp;c red #40]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zodex 6-Day: 1.5 mg (21 ea [DSC]) [scored; contains fd&amp;c red #40 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ZonaCort 11 Day: 1.5 mg (41 ea) [scored; contains fd&amp;c red #40]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ZonaCort 7 Day: 1.5 mg (27 ea) [scored; contains fd&amp;c red #40]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015651\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8016306\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer with meals to help prevent GI upset. May administer antacids between meals to help prevent peptic ulcers.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral concentrate: Use only the calibrated dropper provided. Draw dose into dropper; squeeze dropper contents into a liquid or semi-solid food (water, juice, soda or soda-like beverage, applesauce, pudding). Gently stir for a few seconds. Administer the entire mixture immediately. Do not store for future use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Use preservative-free dosage forms in neonates. May administer  4 mg/mL or 10 mg/mL concentration undiluted over &le;1 minute (Gahart 2015). Rapid administration may be associated with perineal irritation (especially with higher doses); consider further dilution and administration by IV intermittent infusion over 5 to 15 minutes (Allan 1986; Neff 2002; Perron 2003; Singh 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: Administer  4 mg/mL or 10 mg/mL concentration by deep IM injection.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intra-articular: Administer into affected joint using the 4 mg/mL concentration only.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intralesional injection: Administer into affected area using the 4 mg/mL concentration only.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Soft tissue injection: Administer into affected tissue using the 4 mg/mL concentration only.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015652\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Treatment guidelines recommend the use of high dose IV or oral methylprednisolone for acute exacerbations of multiple sclerosis (AAN [Scott 2011], NICE 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Oral, IV or IM injection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Allergic states: </b>Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: seasonal or perennial allergic rhinitis, bronchial asthma, contact dermatitis, atopic dermatitis, serum sickness, drug hypersensitivity reactions; acute noninfectious laryngeal edema, urticarial transfusion reactions (injection only).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Collagen diseases: </b>During an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus or acute rheumatic carditis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dermatologic diseases: </b>Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative dermatitis; exfoliative erythroderma; mycosis fungoides; severe psoriasis; severe seborrheic dermatitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Diagnostic testing: </b>Diagnostic testing of adrenocortical hyperfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Edematous states: </b>To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that because of systemic lupus erythematosus.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endocrine disorders: </b>Primary, secondary, or acute (injection only) adrenocortical insufficiency (hydrocortisone or cortisone is the first choice); preoperatively, and in the event of serious trauma or illness, in adrenal insufficiency or when adrenocortical reserve is doubtful (injection only); shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected (injection only); congenital adrenal hyperplasia; nonsuppurative thyroiditis; hypercalcemia associated with cancer.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>GI diseases: </b>To tide the patient over a critical period of the disease in ulcerative colitis or regional enteritis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hematologic disorders:</b> Immune thrombocytopenia (formerly known as idiopathic thrombocytopenic purpura) in adults (not IM); secondary thrombocytopenia in adults (select cases); acquired (autoimmune) hemolytic anemia; pure red cell aplasia; congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Neoplastic diseases: </b>Palliative management of leukemias and lymphomas in adults and acute leukemia of childhood.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Nervous system: </b>Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Ophthalmic diseases: </b>Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as allergic conjunctivitis; keratitis; allergic corneal marginal ulcers; herpes zoster ophthalmicus; iritis and iridocyclitis; chorioretinitis; anterior segment inflammation; diffuse posterior uveitis and choroiditis; optic neuritis; sympathetic ophthalmia; temporal arteritis; uveitis; ocular inflammatory conditions unresponsive to topical corticosteroids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Respiratory diseases: </b>Symptomatic sarcoidosis; Loeffler syndrome not manageable by other means; berylliosis; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; aspiration pneumonitis; idiopathic eosinophilic pneumonias.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rheumatic disorders: </b>As adjunctive therapy for short-term administration in psoriatic arthritis, rheumatoid arthritis (RA), juvenile RA, ankylosing spondylitis, acute and subacute bursitis, acute nonspecific tenosynovitis, acute gouty arthritis, posttraumatic osteoarthritis, synovitis of osteoarthritis, epicondylitis; treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Miscellaneous: </b>Tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy; trichinosis with neurologic or myocardial involvement.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Intraarticular or soft tissue injection: </b>As adjunctive therapy for short-term administration in synovitis of osteoarthritis, RA, acute and subacute bursitis, acute gouty arthritis, epicondylitis, acute nonspecific tenosynovitis, posttraumatic osteoarthritis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Intralesional injection: </b>Keloids; localized hypertrophic, infiltrated, inflammatory lesions of lichen planus, psoriatic plaques, granuloma annulare, and lichen simplex chronicus (neurodermatitis); discoid lupus erythematosus; necrobiosis lipoidica diabeticorum; alopecia areata; cystic tumors of an aponeurosis or tendon (ganglia)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475108\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Accelerated fetal lung maturation; Chemotherapy-associated nausea and vomiting, prevention; Glucocorticoid remediable aldosteronism, treatment; Immune thrombocytopenia (primary) (children/adolescents); Immune thrombocytopenia, chronic (refractory) (children/adolescents); Multiple myeloma; Prevention and treatment of acute mountain sickness and high altitude cerebral edema</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015647\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dexamethasone may be confused with desoximetasone, dextroamphetamine</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Decadron may be confused with Percodan</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015706\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Some reactions listed are based on reports for other agents in this same pharmacologic class and may not be specifically reported for dexamethasone.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Bradycardia, cardiac arrhythmia, cardiac failure, cardiomegaly, circulatory shock, edema, embolism (fat), hypertension, hypertrophic cardiomyopathy (premature infants), myocardial rupture (post-MI), syncope, tachycardia, thromboembolism, thrombophlebitis, vasculitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Depression, emotional lability, euphoria, headache, increased intracranial pressure, insomnia, malaise, myasthenia, neuritis, neuropathy, paresthesia, personality changes, pseudotumor cerebri (usually following discontinuation), psychic disorder, seizure, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Acne vulgaris, allergic dermatitis, alopecia, atrophic striae, diaphoresis, ecchymoses, erythema, facial erythema, fragile skin, hyperpigmentation, hypertrichosis, hypopigmentation, perianal skin irritation (itching, burning, tingling; following IV injection), petechiae, skin atrophy, skin rash, subcutaneous atrophy, suppression of skin test reaction, urticaria, xeroderma</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Adrenal suppression, carbohydrate intolerance, Cushing syndrome, decreased glucose tolerance, decreased serum potassium, diabetes mellitus, fluid retention, glycosuria, growth suppression (children), hirsutism, HPA-axis suppression, hyperglycemia, hypokalemic alkalosis, menstrual disease, moon face, negative nitrogen balance, protein catabolism, redistribution of body fat, sodium retention, weight gain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal distention, gastrointestinal hemorrhage, gastrointestinal perforation, hiccups, increased appetite, nausea, pancreatitis, peptic ulcer, pruritus ani (following IV injection), ulcerative esophagitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Defective (increased or decreased) spermatogenesis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Kaposi sarcoma, petechial, tumor lysis syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Hepatomegaly, increased serum transaminases</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Anaphylactoid reaction, anaphylaxis, angioedema, hypersensitivity</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection, sterile abscess</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Postinjection flare (intra-articular use)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Amyotrophy, aseptic necrosis of bones (femoral and humoral heads), bone fractures, Charcot-like arthropathy, myasthenia, myopathy (particularly in conjunction with neuromuscular disease or neuromuscular-blocking agents), osteoporosis, rupture of tendon, steroid myopathy, vertebral compression fracture</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Exophthalmos, glaucoma, increased intraocular pressure, subcapsular posterior cataract</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pulmonary edema</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Wound healing impairment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015703\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to dexamethasone or any component of the formulation; systemic fungal infections</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Documentation of allergenic cross-reactivity for corticosteroids is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015704\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Adult patients receiving &gt;20 mg per day of prednisone (or equivalent) may be most susceptible. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do <b>not</b> provide the systemic steroid needed to treat patients having trauma, surgery, or infections.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid reactions: Rare cases of anaphylactoid reactions have been observed in patients receiving corticosteroids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunosuppression: Prolonged use of corticosteroids may increase the incidence of secondary infection, cause activation of latent infections, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to killed or inactivated vaccines. Exposure to chickenpox or measles should be avoided; corticosteroids should not be used to treat ocular herpes simplex. Corticosteroids should not be used for cerebral malaria, fungal infections, or viral hepatitis. Close observation is required in patients with latent tuberculosis and/or TB reactivity; restrict use in active TB (only fulminating or disseminated TB in conjunction with antituberculosis treatment). Amebiasis should be ruled out in any patient with recent travel to tropic climates or unexplained diarrhea prior to initiation of corticosteroids. Use with extreme caution in patients with <i>Strongyloides</i> infections; hyperinfection, dissemination and fatalities have occurred.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Kaposi sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi sarcoma (case reports); if noted, discontinuation of therapy should be considered (Goedert 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myopathy: Acute myopathy has been reported with high dose corticosteroids, usually in patients with neuromuscular transmission disorders; may involve ocular and/or respiratory muscles; monitor creatine kinase; recovery may be delayed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Perineal irritation: Perineal burning, tingling, pain and pruritus have been reported with IV administration. May occur more commonly in females, with higher doses, and with rapid administration. Symptom onset is sudden and usually resolves in &lt;1 minute (Allan 1986; Neff 2002; Perron 2003; Singh 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychiatric disturbances: Corticosteroid use may cause psychiatric disturbances, including depression, euphoria, insomnia, mood swings, personality changes, severe depression to psychotic manifestations. Preexisting psychiatric conditions may be exacerbated by corticosteroid use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal insufficiency: Dexamethasone does not provide any mineralocorticoid activity in adrenal insufficiency (may be employed as a single dose while cortisol assays are performed). In the management/prevention of adrenal crisis in patients with <i>known</i> primary adrenal insufficiency, the Endocrine Society practice guidelines state dexamethasone (intravenous) is the least preferred alternative agent and should be used only if no other glucocorticoid is available. For the treatment of chronic primary adrenal insufficiency (ie, physiologic replacement), dexamethasone (oral) is not recommended due to the risk of Cushingoid side effects (ES [Bornstein 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with HF and/or hypertension; use has been associated with fluid retention, electrolyte disturbances, and hypertension. Use with caution following acute MI; corticosteroids have been associated with myocardial rupture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use corticosteroids with caution in patients with diabetes mellitus; may alter glucose production/regulation leading to hyperglycemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal disease: Use with caution in patients with GI diseases (diverticulitis, fresh intestinal anastomoses, active or latent peptic ulcer, ulcerative colitis, abscess or other pyogenic infection) due to perforation risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Head injury: Increased mortality was observed in patients receiving high-dose IV methylprednisolone. High-dose corticosteroids should not be used for the management of head injury (BTF [Carney 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment, including cirrhosis; long-term use has been associated with fluid retention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; exacerbation of symptoms has occurred especially during initial treatment with corticosteroids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use. Use with caution in patients with a history of ocular herpes simplex; corneal perforation has occurred; do not use in active ocular herpes simplex. Not recommended for the treatment of optic neuritis; may increase frequency of new episodes. Consider routine eye exams in chronic users.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Osteoporosis: Use with caution in patients with osteoporosis; high doses and/or long-term use of corticosteroids have been associated with increased bone loss and osteoporotic fractures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; fluid retention may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorders: Use corticosteroids with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid ones.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly with the smallest possible effective dose for the shortest duration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: May affect growth velocity; growth should be routinely monitored in pediatric patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP [&quot;Inactive&quot; 1997]; Zar 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sulfite: Some products may contain sodium sulfite, a sulfite that may cause allergic-type reactions including anaphylaxis and life-threatening or less severe asthmatic episodes in susceptible patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation of therapy: Withdraw therapy with gradual tapering of dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Epidural injection: Corticosteroids are not approved for epidural injection. Serious neurologic events (eg, spinal cord infarction, paraplegia, quadriplegia, cortical blindness, stroke), some resulting in death, have been reported with epidural injection of corticosteroids, with and without use of fluoroscopy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intra-articular injection: May produce systemic as well as local effects. Appropriate examination of any joint fluid present is necessary to exclude a septic process. Avoid injection into an infected site. Do not inject into unstable joints. Patients should not overuse joints in which symptomatic benefit has been obtained as long as the inflammatory process remains active. Frequent intra-articular injection may result in damage to joint tissues.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Stress: Patients may require higher doses when subject to stress (ie, trauma, surgery, severe infection).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015710\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Induces</b> CYP2A6 (weak/moderate), CYP3A4 (weak), UGT1A1</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015711\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9100&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphotericin B: Corticosteroids (Systemic) may enhance the hypokalemic effect of Amphotericin B. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Androgens: Corticosteroids (Systemic) may enhance the fluid-retaining effect of Androgens. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the bioavailability of Corticosteroids (Oral). Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of Corticosteroids (Systemic). Management: No dose adjustment is needed for single 40 mg aprepitant doses. For other regimens, reduce oral dexamethasone or methylprednisolone doses by 50%, and IV methylprednisolone doses by 25%. Antiemetic regimens containing dexamethasone reflect this adjustment.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asparaginase (E. coli): May increase the serum concentration of Dexamethasone (Systemic). This is thought to be due to an asparaginase-related decrease in hepatic proteins responsible for dexamethasone metabolism.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asparaginase (Erwinia): May increase the serum concentration of Dexamethasone (Systemic). This is thought to be due to an asparaginase-related decrease in hepatic proteins responsible for dexamethasone metabolism.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Axicabtagene Ciloleucel: Corticosteroids (Systemic) may diminish the therapeutic effect of Axicabtagene Ciloleucel.  Management: Avoid use of corticosteroids as premedication before axicabtagene ciloleucel. Corticosteroids may, however, be required for treatment of cytokine release syndrome or neurologic toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the absorption of Corticosteroids (Oral).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcitriol (Systemic): Corticosteroids (Systemic) may diminish the therapeutic effect of Calcitriol (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Caspofungin: Inducers of Drug Clearance may decrease the serum concentration of Caspofungin.  Management: Consider using an increased caspofungin dose of 70 mg daily in adults (or 70 mg/m<sup>2</sup>, up to a maximum of 70 mg, daily in pediatric patients) when coadministered with known inducers of drug clearance.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Corticosteroids may enhance the hyperglycemic effect of Ceritinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: CYP3A4 Inducers (Weak) may decrease the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: Dexamethasone (Systemic) may decrease the serum concentration of Cobicistat. Dexamethasone (Systemic) may also counteract the boosting effects of Cobicistat on some agents.  Management: Consider an alternative corticosteroid. Monitor patients receiving this combination closely for evidence of diminished response to the antiviral regimen.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Dexamethasone (Systemic) may decrease the serum concentration of CycloSPORINE (Systemic). Dexamethasone (Systemic) may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Dexamethasone (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Dexamethasone (Systemic). Management: Consider dexamethasone dose increases in patients receiving strong CYP3A4 inducers and monitor closely for reduced steroid efficacy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Daclatasvir: Dexamethasone (Systemic) may decrease the serum concentration of Daclatasvir.  Management: US labeling recommends increasing the daclatasvir dose to 90 mg once daily if used with dexamethasone. Canadian labeling states that the combination of daclatasvir and dexamethasone is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: Dexamethasone (Systemic) may decrease the serum concentration of Dasatinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitoring clinical response and toxicity closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desirudin: Corticosteroids (Systemic) may enhance the anticoagulant effect of Desirudin. More specifically, corticosteroids may increase hemorrhagic risk during desirudin treatment.  Management: Discontinue treatment with systemic corticosteroids prior to desirudin initiation.  If concomitant use cannot be avoided, monitor patients receiving these combinations closely for clinical and laboratory evidence of excessive anticoagulation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Corticosteroids (Systemic) may enhance the hyponatremic effect of Desmopressin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DilTIAZem: May increase the serum concentration of Corticosteroids (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Elvitegravir: Dexamethasone (Systemic) may decrease the serum concentration of Elvitegravir.  Management: Consider using an alternative corticosteroid.  Monitor patients receiving these agents in combination for diminished antiviral response.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May increase the serum concentration of Corticosteroids (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosamprenavir: Dexamethasone (Systemic) may decrease the serum concentration of Fosamprenavir. Fosamprenavir may increase the serum concentration of Dexamethasone (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of Corticosteroids (Systemic). The active metabolite aprepitant is likely responsible for this effect.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May decrease the serum concentration of Dexamethasone (Systemic). Dexamethasone (Systemic) may decrease the serum concentration of Fosphenytoin. Dexamethasone (Systemic) may increase the serum concentration of Fosphenytoin. Management: Consider dexamethasone dose increases when combined with fosphenytoin and monitor closely for reduced steroid efficacy. Monitor phenytoin levels closely, both increased and decreased phenytoin levels have been reported.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: Dexamethasone (Systemic) may decrease the serum concentration of Imatinib.  Management: Avoid concurrent use of imatinib with dexamethasone when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor clinical response closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indacaterol: May enhance the hypokalemic effect of Corticosteroids (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indium 111 Capromab Pendetide: Corticosteroids (Systemic) may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isoniazid: Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ixabepilone: Dexamethasone (Systemic) may decrease the serum concentration of Ixabepilone.  Management: Avoid this combination whenever possible.  If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m<sup>2</sup> to 60 mg/m<sup>2</sup> (given as a 4-hour infusion), as tolerated, should be considered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lapatinib: Dexamethasone (Systemic) may decrease the serum concentration of Lapatinib.  Management: If therapy overlap cannot be avoided, consider titrating lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenalidomide: Dexamethasone (Systemic) may enhance the thrombogenic effect of Lenalidomide. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Loop Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: Corticosteroids (Systemic) may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mifamurtide: Corticosteroids (Systemic) may diminish the therapeutic effect of Mifamurtide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May diminish the therapeutic effect of Corticosteroids (Systemic). MiFEPRIStone may increase the serum concentration of Corticosteroids (Systemic). Management: Avoid mifepristone in patients who require long-term corticosteroid treatment of serious illnesses or conditions (e.g., for immunosuppression following transplantation). Corticosteroid effects may be reduced by mifepristone treatment.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of Corticosteroids (Systemic).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nalmefene: Dexamethasone (Systemic) may decrease the serum concentration of Nalmefene. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of Dexamethasone (Systemic). Management: Decrease dexamethasone doses to 12 mg on day 1, and if needed based on the emetic potential of the regimen, 8 mg daily on days 2 to 4 of chemotherapy when administered with netupitant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents (Nondepolarizing): May enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nicorandil. Gastrointestinal perforation has been reported in association with this combination. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NiMODipine: CYP3A4 Inducers (Weak) may decrease the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (Nonselective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May decrease the serum concentration of Dexamethasone (Systemic). Dexamethasone (Systemic) may decrease the serum concentration of Phenytoin. Dexamethasone (Systemic) may increase the serum concentration of Phenytoin. Management: Consider dexamethasone dose increases when combined with phenytoin and monitor closely for reduced steroid efficacy. Monitor phenytoin levels closely when combined with dexamethasone, both increased and decreased phenytoin levels have been reported.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Quinolones. Specifically, the risk of tendonitis and tendon rupture may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rilpivirine: Dexamethasone (Systemic) may decrease the serum concentration of Rilpivirine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sargramostim: Corticosteroids (Systemic) may enhance the therapeutic effect of Sargramostim. Specifically, corticosteroids may enhance the myeloproliferative effects of sargramostim. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: Dexamethasone (Systemic) may decrease the serum concentration of Simeprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SUNItinib: Dexamethasone (Systemic) may decrease the serum concentration of SUNItinib. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Corticosteroids (Systemic) may decrease the serum concentration of Tacrolimus (Systemic). Conversely, when discontinuing corticosteroid therapy, tacrolimus concentrations may increase. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: Corticosteroids (Systemic) may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids (Systemic).  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Temsirolimus: Dexamethasone (Systemic) may decrease serum concentrations of the active metabolite(s) of Temsirolimus. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: Dexamethasone (Systemic) may enhance the dermatologic adverse effect of Thalidomide. Dexamethasone (Systemic) may enhance the thrombogenic effect of Thalidomide. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tisagenlecleucel: Corticosteroids (Systemic) may diminish the therapeutic effect of Tisagenlecleucel.  Management: Avoid use of corticosteroids as premedication or at any time during treatment with tisagenlecleucel, except in the case of life-threatening emergency (such as resistant cytokine release syndrome).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Triazolam: Dexamethasone (Systemic) may decrease the serum concentration of Triazolam. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urea Cycle Disorder Agents: Corticosteroids (Systemic) may diminish the therapeutic effect of Urea Cycle Disorder Agents. More specifically, Corticosteroids (Systemic) may increase protein catabolism and plasma ammonia concentrations, thereby increasing the doses of Urea Cycle Disorder Agents needed to maintain these concentrations in the target range. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Vaccines (Live). Corticosteroids (Systemic) may diminish the therapeutic effect of Vaccines (Live).  Management: Doses equivalent to less than 2 mg/kg or 20 mg per day of prednisone administered for less than 2 weeks are not considered sufficiently immunosuppressive to create vaccine safety concerns. Higher doses and longer durations should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voriconazole: Dexamethasone (Systemic) may decrease the serum concentration of Voriconazole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Warfarin: Corticosteroids (Systemic) may enhance the anticoagulant effect of Warfarin. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015698\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015699\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed with corticosteroids in animal reproduction studies. Dexamethasone crosses the placenta (Brownfoot 2013); and is partially metabolized by placental enzymes to an inactive metabolite (Murphy 2007). Some studies have shown an association between first trimester systemic corticosteroid use and oral clefts or decreased birth weight; however, information is conflicting and may be influenced by maternal dose/indication for use (Lunghi 2010; Park-Wyllie 2000; Pradat 2003). Hypoadrenalism may occur in newborns following maternal use of corticosteroids during pregnancy; monitor.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Because antenatal corticosteroid administration may reduce the incidence of intraventricular hemorrhage, necrotizing enterocolitis, neonatal mortality, and respiratory distress syndrome, the injection is often used for antenatal fetal lung maturation in patients with preterm premature rupture of membranes or preterm labor who are at risk of preterm delivery (most data is available for betamethasone). A single course of corticosteroids is recommended for women between 24 and 34 weeks' gestation who are at risk of delivering within 7 days, including those with ruptured membranes or multiple gestations. A single course of corticosteroids may be considered for women beginning at 23 weeks' gestation, who are at risk of delivering within 7 days, in consultation with the family. In addition, a single course of corticosteroids may be given to women between 34 0/7 weeks and 36 6/7 weeks who are at risk of preterm delivery within 7 days and who have not previously received corticosteroids; use of concomitant tocolytics is not currently recommended and administration of late preterm corticosteroids has not been evaluated in women with intrauterine infection, multiple gestations, pregestational diabetes, or women who delivered previously by cesarean section at term. Multiple repeat courses are not recommended. However, in women with pregnancies less than 34 weeks' gestation at risk for delivery within 7 days and who had a course of antenatal corticosteroids &gt;14 days prior, a single repeat course may be considered; use of a repeat course in women with premature rupture of membranes is controversial (ACOG 171 2016; ACOG 172 2016; ACOG 677 2016).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">When systemic corticosteroids are needed in pregnancy, it is generally recommended to use the lowest effective dose for the shortest duration of time, avoiding high doses during the first trimester (Leachman 2006; Lunghi 2010; Makol 2011; &Oslash;stensen 2009). Dexamethasone should not be used to treat primary adrenal insufficiency in pregnant women (Bornstein 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015702\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Corticosteroids are present in breast milk; information specific to dexamethasone has not been located.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The manufacturer notes that when used systemically, maternal use of corticosteroids have the potential to cause adverse events in a breastfeeding infant (eg, growth suppression, interfere with endogenous corticosteroid production). Due to the potential for serious adverse reactions in the breastfeeding infant, the manufacturer recommends a decision be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the mother. Single doses of dexamethasone are considered compatible with breastfeeding; information related to prolonged use is not available (WHO 2002). If there is concern about exposure to the infant, some guidelines recommend waiting 4 hours after the maternal dose of an oral systemic corticosteroid before breastfeeding in order to decrease potential exposure to the breastfed infant (based on a study using prednisolone) (Bae 2012; Leachman 2006; Makol 2011; Ost 1985).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015756\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">May be taken with meals to decrease GI upset. May need diet with increased potassium, pyridoxine, vitamin C, vitamin D, folate, calcium, and phosphorus.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8016312\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Hemoglobin, occult blood loss, blood pressure, serum potassium, glucose, bone mineral density; IOP with systemic use &gt;6 weeks;  weight and height in children;  HPA axis suppression</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015721\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">A long acting corticosteroid with minimal sodium-retaining potential. Decreases inflammation by suppression of neutrophil migration, decreased production of inflammatory mediators, and reversal of increased capillary permeability; suppresses normal immune response. Dexamethasone's mechanism of antiemetic activity is unknown.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015724\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: IV: Rapid</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immune thrombocytopenia: Oral: Initial response: 2 to 14 days; Peak response: 4 to 28 days (Neunert 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: IV: Short</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: 61% to 86% (Czock 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extremely low birth-weight infants with BPD: 9.26 &plusmn; 3.34 hours (range: 5.85 to 16.1 hours) (Charles 1993)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 4 months to 16 years: 4.34 &plusmn; 4.14 hours (range: 2.33 to 9.54 hours) (Richter 1983)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Oral: 4 &plusmn; 0.9 hours (Czock 2005); IV: ~1 to 5 hours (Hochhaus 2001; Miyabo 1981; Rohdewald 1987; T&oacute;th 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Oral: 1 to 2 hours (Czock 2005); IM: ~30 to 120 minutes (Egerman 1997; Hochhaus 2001); IV: 5 to 10 minutes (free dexamethasone) (Miyabo 1981; Rohdewald 1987)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (~10%) (Duggan 1975; Miyabo 1981)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8016331\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Concentrate</b> (Dexamethasone Intensol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (30 mL): $32.17</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Elixir</b> (Dexamethasone Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg/5 mL (237 mL): $63.68</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (DoubleDex Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (1): $598.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (MAS Care-Pak Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (1): $605.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (ReadySharp Dexamethasone Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (1): $241.26</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Dexamethasone Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg/5 mL (240 mL): $63.69</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Dexamethasone Sod Phos-NaCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 mg/50 mL 0.9% (50 mL): $6.97</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/50 mL 0.9% (50 mL): $7.16</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12 mg/50 mL 0.9% (50 mL): $7.39</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/50 mL 0.9% (50 mL): $8.30</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Dexamethasone Sod Phosphate PF Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (1 mL): $2.04</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Dexamethasone Sodium Phosphate Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg/mL (1 mL): $1.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (1 mL): $1.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/5 mL (5 mL): $1.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/10 mL (10 mL): $4.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">120 mg/30 mL (30 mL): $34.13</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Dexamethasone Sodium Phosphate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/2.5 mL (2.5 mL): $6.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet Therapy Pack</b> (DexPak 10 Day Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5MG (35) (35): $339.88</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet Therapy Pack</b> (DexPak 13 Day Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5MG (51) (51): $495.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet Therapy Pack</b> (DexPak 6 Day Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5MG (21) (21): $203.90</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet Therapy Pack</b> (LoCort 11-Day Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5MG (41) (41): $339.49</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet Therapy Pack</b> (LoCort 7-Day Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5MG (27) (27): $203.49</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet Therapy Pack</b> (TaperDex 12-Day Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5MG (49) (49): $278.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet Therapy Pack</b> (TaperDex 6-Day Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5MG (21) (21): $226.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet Therapy Pack</b> (ZonaCort 11 Day Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5MG (41) (41): $719.95</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet Therapy Pack</b> (ZonaCort 7 Day Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5MG (27) (27): $699.95</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Decadron Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (100): $189.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.75 mg (100): $283.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (100): $1,512.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 mg (100): $2,268.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Dexamethasone Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (100): $13.81</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.75 mg (100): $24.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (100): $29.74</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5 mg (100): $54.79</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (100): $59.47</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (100): $118.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 mg (100): $178.42</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961968\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aacidexam (BE);</li>\n      <li>Alin (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Asiadexa (VN);</li>\n      <li>Camidexon (ID);</li>\n      <li>Corodex (UY);</li>\n      <li>Cortyk (CL);</li>\n      <li>D Cort (BD);</li>\n      <li>Decadron (AE, BH, CO, CY, EC, IT, JO, KW, LB, PY, QA, SA);</li>\n      <li>Decan (PH, SG, TW);</li>\n      <li>Decasone (ZA);</li>\n      <li>Decdan (IN);</li>\n      <li>Dectancyl (VN);</li>\n      <li>Desalark (IT);</li>\n      <li>Dexa-Sine (BE);</li>\n      <li>Dexacor (BD);</li>\n      <li>Dexacort Forte (IL);</li>\n      <li>Dexaflam (DE);</li>\n      <li>Dexafree (CH, FR, PL, PT);</li>\n      <li>Dexamed (CZ, JO, RO, SG, TR);</li>\n      <li>Dexamed Elixir (LK);</li>\n      <li>Dexamet Solution for Injection (HK);</li>\n      <li>Dexazone (QA);</li>\n      <li>Dexcor (BD);</li>\n      <li>Dexmethsone (AU, NZ);</li>\n      <li>Dexo (ET);</li>\n      <li>Dexona (ET, IN);</li>\n      <li>Dexona-E (LK);</li>\n      <li>Dexone (ZW);</li>\n      <li>Dexovit (LK);</li>\n      <li>Fortecortin (AT, BG, CH, DE, ES);</li>\n      <li>Lenadex (JP);</li>\n      <li>Lodexa (TH);</li>\n      <li>Lodexa-5 (TH);</li>\n      <li>Maradex (VE);</li>\n      <li>Martapan (GB);</li>\n      <li>Medicort (PE);</li>\n      <li>Meradexone (BD);</li>\n      <li>Metacort (PH);</li>\n      <li>Methodex (LK);</li>\n      <li>Millicorten (QA);</li>\n      <li>Naxidex (LK);</li>\n      <li>Nexadron Oftal (AR);</li>\n      <li>Odeson (BD);</li>\n      <li>Oftan Dexa (EE);</li>\n      <li>Opnol (SE);</li>\n      <li>Oradexon (CL, EG, FI, ID, NL, PT, QA, SA);</li>\n      <li>Ordex (BD);</li>\n      <li>Ronic (ET);</li>\n      <li>Sonexa (BD);</li>\n      <li>Spersadex (CH, DE, HK, NO, ZA);</li>\n      <li>Sterodex (IL);</li>\n      <li>Steron (BD);</li>\n      <li>Vedex (LK);</li>\n      <li>Vextasone (MY);</li>\n      <li>Vherdex (PH);</li>\n      <li>Visumetazone (IT);</li>\n      <li>Wymesone (IN);</li>\n      <li>Zenos (QA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abraham E and Evans T, &ldquo;Corticosteroids and Septic Shock [editorial],&rdquo; <i>JAMA</i>, 2002, 288(7):886-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/12186608/pubmed\" target=\"_blank\" id=\"12186608\">12186608</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26695585\"></a>American College Of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 171: Management of Preterm Labor. <i>Obstet Gynecol</i>. 2016;128(4):e155-164. doi: 10.1097/AOG.0000000000001711.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/27661654/pubmed\" target=\"_blank\" id=\"27661654\">27661654</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26695586\"></a>American College Of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 172: Premature Rupture of Membranes. <i>Obstet Gynecol</i>. 2016;128(4):e165-177. doi: 10.1097/AOG.0000000000001712.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/27661655/pubmed\" target=\"_blank\" id=\"27661655\">27661655</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27661658\"></a>American College Of Obstetricians and Gynecologists (ACOG). Committee Opinion No. 677: Antenatal Corticosteroid Therapy for Fetal Maturation. <i>Obstet Gynecol</i>. 2016;128(4):e187-194. doi:10.1097/AOG.0000000000001715.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/27661658/pubmed\" target=\"_blank\" id=\"27661658\">27661658</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Allan SG, Leonard RCF. Dexamethasone antiemesis and side-effects. <i>Lancet</i>. 1986;1(8488):1035.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/2871314/pubmed\" target=\"_blank\" id=\"2871314\">2871314</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Infectious Diseases, &ldquo;Dexamethasone Therapy for Bacterial Meningitis in Infants and Children,&rdquo; <i>Pediatrics</i>, 1990, 86(1):130-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/2193301/pubmed\" target=\"_blank\" id=\"2193301\">2193301</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anene O, Meert KL, Uy H, Simpson P, Sarnaik AP. Dexamethasone for the prevention of postextubation airway obstruction: a prospective, randomized, double-blind, placebo-controlled trial. <i>Crit Care Med</i>. 1996;24(10):1666-1669.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/8874303/pubmed\" target=\"_blank\" id=\"8874303\">8874303</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Annane D, Sebille V, Charpentier C, et al, &ldquo;Effect of Treatment With Low Doses of Hydrocortisone and Fludrocortisone on Mortality in Patients With Septic Shock,&rdquo; <i>JAMA</i>, 2002, 288(7):862-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/12186604/pubmed\" target=\"_blank\" id=\"12186604\">12186604</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007:110, 176.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bae YS, Van Voorhees AS, Hsu S, et al, &quot;Review of Treatment Options For Psoriasis in Pregnant or Lactating Women: From the Medical Board of the National Psoriasis Foundation,&quot; <i>J Am Acad Dermatol</i>, 2012, 67(3):459-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/22018758/pubmed\" target=\"_blank\" id=\"22018758\">22018758</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bahal N and Nahata MC, &ldquo;The Role of Corticosteroids in Infants and Children With Bacterial Meningitis,&rdquo; <i>DICP</i>, 1991, 25(5):542-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/2068839/pubmed\" target=\"_blank\" id=\"2068839\">2068839</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bjornson CL, Klassen TP, Williamson J, et al, &quot;A Randomized Trial of a Single Dose of Oral Dexamethasone for Mild Croup,&quot; <i>N Engl J Med</i>, 2004, 351(13):1306-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/15385657/pubmed\" target=\"_blank\" id=\"15385657\">15385657</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(2):364-389. doi: 10.1210/jc.2015-1710.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/26760044/pubmed\" target=\"_blank\" id=\"26760044\">26760044</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bratton SL, Chestnut RM, Ghajar J, et al, &ldquo;Guidelines for the Management of Severe Traumatic Brain Injury. XV. Steroids,&rdquo; <i>J Neurotrauma</i>, 2007, 24(Suppl 1):91-5<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/17511554/pubmed\" target=\"_blank\" id=\"17511554\">17511554</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23990333\"></a>Brownfoot FC, Gagliardi DI, Bain E, et al. Different corticosteroids and regimens for accelerating fetal lung maturation for women at risk of preterm birth. <i>Cochrane Database Syst Rev</i>. 2013 Aug 29;8:CD006764. doi:10.1002/14651858.CD006764.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/23990333/pubmed\" target=\"_blank\" id=\"23990333\">23990333</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carney N, Totten AM, O'Reilly C, et al; Brain Trauma Foundation. Guidelines for the management of severe traumatic brain injury, fourth edition [published online ahead of print September 20, 2016]. <i>Neurosurgery</i>. doi: 10.1227/NEU.0000000000001432.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/27654000/pubmed\" target=\"_blank\" id=\"27654000\">27654000</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Charles B, Schild P, Steer P, Cartwright D, Donovan T. Pharmacokinetics of dexamethasone following single-dose intravenous administration to extremely low birth weight infants. <i>Dev Pharmacol Ther</i>. 1993;20(3-4):205-210.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/7828455/pubmed\" target=\"_blank\" id=\"7828455\">7828455</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9407939\"></a>Chen JS, Wu JM, Chen YJ, Yeh TF. Pulsed high-dose dexamethasone therapy in children with chronic idiopathic thrombocytopenic purpura. <i>J Pediatr Hematol Oncol</i>. 1997;19(6):526-529.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/9407939/pubmed\" target=\"_blank\" id=\"9407939\">9407939</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cheng Y, Wong RS, Soo YO, et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. <i>N Engl J Med</i>. 2003;349(9):831-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/12944568 /pubmed\" target=\"_blank\" id=\"12944568 \">12944568 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cinvanti (aprepitant IV) [prescribing information]. San Diego, CA: Heron Therapeutics, Inc; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cooper MS and Stewart PM, &ldquo;Corticosteroid Insufficiency in Acutely Ill Patients,&rdquo; <i>N Engl J Med</i>, 2003, 348(8):727-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/12594318/pubmed\" target=\"_blank\" id=\"12594318\">12594318</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Coryell WH, &ldquo;Clinical Assessment of Suicide Risk in Depressive Disorder,&rdquo; <i>CNS Spectr</i>, 2006, 11(6):455-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/16816777/pubmed\" target=\"_blank\" id=\"16816777\">16816777</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Coursin DB and Wood KE, &ldquo;Corticosteroid Supplementation for Adrenal Insufficiency,&rdquo; <i>JAMA</i>, 2002, 287(2):236-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/11779267/pubmed\" target=\"_blank\" id=\"11779267\">11779267</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Couser RJ, Ferrara TB, Falde B, et al, &ldquo;Effectiveness of Dexamethasone in Preventing Extubation Failure in Preterm Infants at Increased Risk for Airway Edema,&rdquo; <i>J Pediatr</i>, 1992, 121(4):591-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/1403397/pubmed\" target=\"_blank\" id=\"1403397\">1403397</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Czock D, Keller F, Rasche FM, H&auml;ussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. <i>Clin Pharmacokinet</i>. 2005;44(1):61-98.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/15634032/pubmed\" target=\"_blank\" id=\"15634032\">15634032</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Jonghe B, Sharshar T, Lefaucheur JP, et al, &ldquo;Paresis Acquired in the Intensive Care Unit. A Prospective Multicenter Study,&rdquo; <i>JAMA</i>, 2002, 288(22):2859-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/12472328/pubmed\" target=\"_blank\" id=\"12472328\">12472328</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dellinger RP, Levy MM, Rhodes A, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012,&rdquo; <i>Crit Care Med</i>, 2013, 41(2):580-637.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/23353941/pubmed\" target=\"_blank\" id=\"23353941\">23353941</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dexamethasone elixir [prescribing information]. Morton Grove, IL: Morton Grove Pharmaceuticals; April 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Dexamethasone, Granisetron, or Both for the Prevention of Nausea and Vomiting During Chemotherapy for Cancer. The Italian Group for Antiemetic Research,&rdquo; <i>N Engl J Med</i>, 1995, 332(1):1-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/7990859/pubmed\" target=\"_blank\" id=\"7990859\">7990859</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dexamethasone Sodium Phosphate injection [prescribing information]. Schaumburg, IL: APP Pharmaceuticals; January 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dexamethasone Sodium Phosphate PF injection [prescribing information]. Lake Zurich, IL: Fresenius Kabi; August 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dexamethasone tablets, dexamethasone oral solution, Intensol [prescribing information]. Columbus, OH: Roxane Laboratories; February 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dexamethasone tablets and dexamethasone oral solution [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals Corp.; March 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DexPak 13 Day TaperPak, 10 Day TaperPak, and 6 Day TaperPak (dexamethasone) [prescribing information]. Richmond, VA: ECR; June 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. <i>N Engl J Med</i>. 2016a;375(14):1319-1331.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/27705267/pubmed\" target=\"_blank\" id=\"27705267\">27705267</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dimopoulos MA, Sonneveld P, Leung N, et al. International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment. <i>J Clin Oncol</i>. 2016b;34(13):1544-1557.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/26976420/pubmed\" target=\"_blank\" id=\"26976420\">26976420</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Duggan DE, Matalia N, Ditzler, CA, et al, &ldquo;Bioavailability of Oral Dexamethasone,&rdquo; <i>Clin Pharmacol Ther</i>, 1975, 18(2):205-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/1097154/pubmed\" target=\"_blank\" id=\"1097154\">1097154</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Holdsworth M, et al; Pediatric Oncology Group of Ontario. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2013;60(7):1073-1082. doi: 10.1002/pbc.24508.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/23512831/pubmed\" target=\"_blank\" id=\"23512831\">23512831</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Durand M, Sardesai S, and McEvoy C, &ldquo;Effects of Early Dexamethasone Therapy on Pulmonary Mechanics and Chronic Lung Disease in Very Low Birth Weight Infants: A Randomized, Controlled Trial,&rdquo; <i>Pediatrics</i>, 1995, 95(4):584-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/7700763/pubmed\" target=\"_blank\" id=\"7700763\">7700763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Edwards P, Arango M, Balica L, et al, &ldquo;Final Results of MRC Crash, A Randomized Placebo-Controlled Trial of Intravenous Corticosteroid in Adults With Head Injury &ndash; Outcomes at 6 Months,&rdquo; <i>Lancet,</i> 2005, 365(9475):1957-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/15936423/pubmed\" target=\"_blank\" id=\"15936423\">15936423</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Egerman RS, Pierce WF 4th, Andersen RN, Umstot ES, Carr TL, Sibai BM. A comparison of the bioavailability of oral and intramuscular dexamethasone in women in late pregnancy. <i>Obstet Gynecol</i>. 1997;89(2):276-280.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/9015035/pubmed\" target=\"_blank\" id=\"9015035\">9015035</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/26934393/pubmed\" target=\"_blank\" id=\"26934393\">26934393</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gahart BL, Nazareno AR. <i>2015 Intravenous Medications: A Handbook for Nurses and Health Professionals</i>, 31st ed. St Louis, MO: Elsevier/Mosby; 2015:371.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention 2014. Available from http://www.ginasthma.org.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goedert JJ, Vitale F, Lauria C, et al, &ldquo;Risk Factors for Classical Kaposi's Sarcoma,&rdquo; <i>J Natl Cancer Inst</i>, 2002, 94(22):1712-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/12441327/pubmed\" target=\"_blank\" id=\"12441327\">12441327</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gupta P, Bhatia V. Corticosteroid physiology and principles of therapy.<i> Indian J Pediatr</i>. 2008;75(10):1039-1044.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/19023528/pubmed\" target=\"_blank\" id=\"19023528\">19023528</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12571466\"></a>Hedlund-Treutiger I, Henter JI, Elinder G. Randomized study of IVIg and high-dose dexamethasone therapy for children with chronic idiopathic thrombocytopenic purpura. <i>J Pediatr Hematol Oncol</i>. 2003;25(2):139-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/12571466/pubmed\" target=\"_blank\" id=\"12571466\">12571466</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hegenbarth MA;American Academy of Pediatrics Committee on Drugs. Preparing for pediatric emergencies: drugs to consider. <i>Pediatrics.</i> 2008;121(2):433-443.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/18245435/pubmed\" target=\"_blank\" id=\"18245435\">18245435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017;35(28):3240-3261. doi: 10.1200/JCO.2017.74.4789.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/28759346/pubmed\" target=\"_blank\" id=\"28759346\">28759346</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hochberg MC, Altman RD, April KT, et al, &ldquo;American College of Rheumatology 2012 Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee,&rdquo; <i>Arthritis Care Res (Hoboken)</i>, 2012, 64(4):465-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/22563589/pubmed\" target=\"_blank\" id=\"22563589\">22563589</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hochhaus G, Barth J, al-Fayoumi S, et al. Pharmacokinetics and pharmacodynamics of dexamethasone sodium-m-sulfobenzoate (DS) after intravenous and intramuscular administration: a comparison with dexamethasone phosphate (DP). <i>J Clin Pharmacol</i>. 2001;41(4):425-434.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/11304899/pubmed\" target=\"_blank\" id=\"11304899\">11304899</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Keeney GE, Gray MP, Morrison AK, et al. Dexamethasone for acute asthma exacerbations in children: a meta-analysis. <i>Pediatrics</i>. 2014;133(3):493-499.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/24515516/pubmed\" target=\"_blank\" id=\"24515516\">24515516</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Khemani RG, Randolph A, Markovitz B. Corticosteroids for the Prevention and Treatment of Post-Extubation Stridor in Neonates, Children and Adults. <i>Cochrane Database Syst Rev.</i> 2009;(3):CD001000.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/19588321/pubmed\" target=\"_blank\" id=\"19588321\">19588321</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9003846\"></a>K&uuml;hne T, Freedman J, Semple JW, Doyle J, Butchart S, Blanchette VS. Platelet and immune responses to oral cyclic dexamethasone therapy in childhood chronic immune thrombocytopenic purpura. <i>J Pediatr</i>. 1997 Jan;130(1):17-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/9003846/pubmed\" target=\"_blank\" id=\"9003846\">9003846</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kris MG, Baltzer L, Pisters KM, et al, &ldquo;Enhancing the Effectiveness of the Specific Serotonin Antagonists. Combination Antiemetic Therapy With Dexamethasone,&rdquo; <i>Cancer</i>, 1993, 72(11 Suppl):3436-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/8242576/pubmed\" target=\"_blank\" id=\"8242576\">8242576</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kyle RA and Rajkumar SV, &ldquo;Multiple Myeloma,&rdquo; <i>N Engl J Med</i>, 2004, 351(18): 1860-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/15575057/pubmed\" target=\"_blank\" id=\"15575057\">15575057</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Latreille J, Stewart D, Laberge F, et al, &ldquo;Dexamethasone Improves the Efficacy of Granisetron in the First 24 h Following High-Dose Cisplatin Chemotherapy,&rdquo; <i>Support Care Cancer</i>, 1995, 3(5):307-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/8520877/pubmed\" target=\"_blank\" id=\"8520877\">8520877</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leachman SA and Reed BR, &quot;The Use of Dermatologic Drugs in Pregnancy and Lactation,&quot; <i>Dermatol Clin</i>, 2006, 24(2):167-97, vi.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/16677965/pubmed\" target=\"_blank\" id=\"16677965\">16677965</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee CH, Peng MJ, Wu CL. Dexamethasone to prevent postextubation airway obstruction in adults: a prospective, randomized, double-blind, placebo-controlled study. <i>Crit Care</i>. 2007;11(4):R72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/17605780/pubmed\" target=\"_blank\" id=\"17605780\">17605780</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26035255\"></a>Lonial S, Dimopoulos M, Palumbo A, et al; ELOQUENT-2 Investigators. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. <i>N Engl J Med</i>. 2015;373(7):621-631.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/26035255/pubmed\" target=\"_blank\" id=\"26035255\">26035255</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lunghi L, Pavan B, Biondi C, et al, &quot;Use of Glucocorticoids in Pregnancy,&quot;<i> Curr Pharm Des</i>, 2010, 16(32):3616-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/20977425/pubmed\" target=\"_blank\" id=\"20977425\">20977425</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Luks AM, McIntosh SE, Grissom CK, et al, &ldquo;Wilderness Medical Society Consensus Guidelines for the Prevention and Treatment of Acute Altitude Illness,&rdquo; <i>Wilderness Environ Med</i>, 2010, 21(2):146-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/20591379/pubmed\" target=\"_blank\" id=\"20591379\">20591379</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mazzucconi MG, Fazi P, Bernasconi S, et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. <i>Blood</i>. 2007;109(4):1401-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/17077333/pubmed\" target=\"_blank\" id=\"17077333\">17077333</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Makol A, Wright K, and Amin S, &quot;Rheumatoid Arthritis and Pregnancy: Safety Considerations in Pharmacological Management,&quot; <i>Drugs</i>, 2011, 71(15):1973-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/21985166/pubmed\" target=\"_blank\" id=\"21985166\">21985166</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mann JJ, Currier D, Stanley B, et al, &ldquo;Can Biological Tests Assist Prediction of Suicide in Mood Disorders?&rdquo; <i>Int J Neuropsychopharmacol</i>, 2006, 9(4):465-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/15967058/pubmed\" target=\"_blank\" id=\"15967058\">15967058</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marik PE, Pastores SM, Annane D, et al, &ldquo;Recommendations for the Diagnosis and Management of Corticosteroid Insufficiency in Critically Ill Adult Patients: Consensus Statements From an International Task Force by the American College of Critical Care Medicine,&rdquo; <i>Crit Care Med</i>, 2008, 36(6):1937-49.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/18496365/pubmed\" target=\"_blank\" id=\"18496365\">18496365</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McDonnell M and Evans N, &ldquo;Upper and Lower Gastrointestinal Complications With Dexamethasone Despite H2 Antagonists,&rdquo; <i>J Paediatr Child Health</i>, 1995, 31(2):152-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/7794619/pubmed\" target=\"_blank\" id=\"7794619\">7794619</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McGee S and Hirschmann J, &ldquo;Use of Corticosteroids in Treating Infectious Diseases,&rdquo; <i>Arch Intern Med</i>, 2008, 168(10):1034-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/18504331/pubmed\" target=\"_blank\" id=\"18504331\">18504331</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miyabo S, Nakamura T, Kuwazima S, Kishida S. A comparison of the bioavailability and potency of dexamethasone phosphate and sulphate in man. <i>Eur J Clin Pharmacol</i>. 1981;20(4):277-282.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/6273180/pubmed\" target=\"_blank\" id=\"6273180\">6273180</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      Moreau P, Masszi T, Grzasko N, et al. Izazomib, an investigational oral proteasome inhibitor (PI), in combination with lenalidomide and dexamethasone (IRd), significantly extends progression-free survival (PFS) for patients (Pts) with relapsed and/or refractory multiple myeloma (RRMM). The phase 3 Tourmaline-MM1 study (NCT01564537) [abstract]. Presented at the 2015 ASH Annual Meeting.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murphy VE, Fittock RJ, Zarzycki PK, et al, &ldquo;Metabolism of Synthetic Steroids by the Human Placenta,&rdquo; <i>Placenta</i>, 2007, 28(1):39-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/16549198/pubmed\" target=\"_blank\" id=\"16549198\">16549198</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Institute for Health and Care Excellence (NICE). Multiple sclerosis in adults: management. Clinical guideline [CG186]. http://nice.org.uk/guidance/cg186. Published October 8, 2014. Accessed October 21, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neff SPW, Stapelberg F, Warmington A. Excruciating perineal pain after intravenous dexamethasone. <i>Anaesth Intensive Care</i>. 2002;30(3):370-371.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/12075649/pubmed\" target=\"_blank\" id=\"12075649\">12075649</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21325604\"></a>Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. <i>Blood</i>. 2011;117(16):4190-4207.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/21325604/pubmed\" target=\"_blank\" id=\"21325604\">21325604</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ng PC, &ldquo;The Effectiveness and Side Effects of Dexamethasone in Preterm Infants With Bronchopulmonary Dysplasia,&rdquo; <i>Arch Dis Child</i>, 1993, 68(3 Spec No):330-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/8466274/pubmed\" target=\"_blank\" id=\"8466274\">8466274</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ost L, Wettrell G, Bjorkhem I, et al, &quot;Prednisolone Excretion in Human Milk,&quot; <i>J Pediatr</i>, 1985, 106(6):1008-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/3998938/pubmed\" target=\"_blank\" id=\"3998938\">3998938</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &Oslash;stensen M and Forger F, &quot;Management of RA Medications in Pregnant Patients,&quot; <i>Nat Rev Rheumatol</i>, 2009, 5(7):382-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/19506586/pubmed\" target=\"_blank\" id=\"19506586\">19506586</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. <i>N Engl J Med</i>. 2016;375(8):754-766.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/27557302/pubmed\" target=\"_blank\" id=\"27557302\">27557302</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Park-Wyllie L, Mazzotta P, Pastuszak A, et al, &quot;Birth defects After Maternal Exposure to Corticosteroids: Prospective Cohort Study and Meta-Analysis of Epidemiological Studies,&quot; <i>Teratology</i>, 2000, 62(6):385-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/11091360/pubmed\" target=\"_blank\" id=\"11091360\">11091360</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patel P, Robinson PD, Thackray J, et al. Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: a focused update. <i>Pediatr Blood Cancer</i>. 2017;64(10). doi: 10.1002/pbc.26542.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/28453189/pubmed\" target=\"_blank\" id=\"28453189\">28453189</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perron G, Dolbec P, Germain J, B&eacute;chard P. Perineal pruritus after i.v. dexamethasone administration. <i>Can J Anaesth,</i> 2003;50(7):749-750.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/12944454/pubmed\" target=\"_blank\" id=\"12944454\">12944454</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peterson C, Hursti TJ, Borjeson S, et al, &ldquo;Single High-Dose Dexamethasone Improves the Effect of Ondansetron on Acute Chemotherapy-Induced Nausea and Vomiting But Impairs the Control of Delayed Symptoms,&rdquo; <i>Support Care Cancer</i>, 1996, 4(6):440-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/8961475/pubmed\" target=\"_blank\" id=\"8961475\">8961475</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pollard AJ, Niermeyer S, Barry P, et al, &ldquo;Children at High Altitude: An International Consensus Statement by an Ad Hoc Committee of the International Society for Mountain Medicine, March 12, 2001,&rdquo; <i>High Alt Med Biol</i>, 2001, 2(3):389-403.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/11682018/pubmed\" target=\"_blank\" id=\"11682018\">11682018</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pradat P, Robert-Gnansia E, Di Tanna GL, et al, &ldquo;First Trimester Exposure to Corticosteroids and Oral Clefts,&rdquo; <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(12):968-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/14745915/pubmed\" target=\"_blank\" id=\"14745915\">14745915</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19846889\"></a>Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. <i>Blood</i>. 2010;115(2):168-186.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/19846889/pubmed\" target=\"_blank\" id=\"19846889\">19846889</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11445789\"></a>Qureshi F, Zaritsky A, Poirier MP. Comparative efficacy of oral dexamethasone versus oral prednisone in acute pediatric asthma. <i>J Pediatr</i>. 2001;139(1):20-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/11445789/pubmed\" target=\"_blank\" id=\"11445789\">11445789</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25179689\"></a>Raftopoulos H, Cooper W, O'Boyle E, et al. Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial. <i>Support Care Cancer</i>. 2015 ;23(3):723-732.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/25179689/pubmed\" target=\"_blank\" id=\"25179689\">25179689</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19853510\"></a>Rajkumar SV, Jacobus S, Callander NS, et al; Eastern Cooperative Oncology Group. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. <i>Lancet Oncol</i>. 2010;11(1):29-37. doi: 10.1016/S1470-2045(09)70284-0.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/19853510/pubmed\" target=\"_blank\" id=\"19853510\">19853510</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Richter O, Ern B, Reinhardt D, Becker B. Pharmacokinetics of dexamethasone in children. <i>Pediatr Pharmacol (New York)</i>. 1983;3(3-4):329-337.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/6677878/pubmed\" target=\"_blank\" id=\"6677878\">6677878</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rittichier KK and Ledwith CA, &quot;Outpatient Treatment of Moderate Croup With Dexamethasone: Intramuscular Versus Oral Dosing,&quot; <i>Pediatrics</i>, 2000, 106(6):1344-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/11099587/pubmed\" target=\"_blank\" id=\"11099587\">11099587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roberts I, Yates D, Sandercock P, et al, &ldquo;Effect of Intravenous Corticosteroids on Death Within 14 days in 10,008 Adults With Clinically Significant Head Injury (MRC CRASH trial): Randomised Placebo-Controlled Trial,&rdquo; <i>Lancet</i>, 2004, 364(9442):1321-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/15474134/pubmed\" target=\"_blank\" id=\"15474134\">15474134</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rohdewald P, M&ouml;llmann H, Barth J, Rehder J, Derendorf H. Pharmacokinetics of dexamethasone and its phosphate ester. <i>Biopharm Drug Dispos</i>. 1987;8(3):205-212.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/3593899/pubmed\" target=\"_blank\" id=\"3593899\">3593899</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol</i>. 2016;27(suppl 5):v119-v133.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/27664248/pubmed\" target=\"_blank\" id=\"27664248\">27664248</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Russell K, Wiebe N, Saenz A, et al, &quot;Glucocorticoids for Croup,&quot; <i>Cochrane Database Syst Rev</i>, 2004, (1):CD001955.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/14973975/pubmed\" target=\"_blank\" id=\"14973975\">14973975</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ruvinsky ED, Douvas SG, Roberts WE, et al, &ldquo;Maternal Administration of Dexamethasone in Severe Pregnancy-Induced Hypertension,&rdquo; <i>Am J Obstet Gynecol</i>, 1984, 149(7):722-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/6465221/pubmed\" target=\"_blank\" id=\"6465221\">6465221</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Salem M, Tainsh RE Jr, Bromberg J, et al, &ldquo;Perioperative Glucocorticoid Coverage. A Reassessment 42 Years After Emergence of a Problem,&rdquo; <i>Ann Surg</i>, 1994, 219(4):416-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/8161268/pubmed\" target=\"_blank\" id=\"8161268\">8161268</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24007748\"></a>San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. <i>Lancet Oncol</i>. 2013;14(11):1055-1066. doi: 10.1016/S1470-2045(13)70380-2. doi: 10.1016/S1470-2045(13)70380-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/24007748/pubmed\" target=\"_blank\" id=\"24007748\">24007748</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22156988\"></a>Scott TF, Frohman EM, De Seze J, Gronseth GS, Weinshenker BG; Therapeutics and Technology Assessment Subcommittee of American Academy of Neurology. Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2011;77(24):2128-2134. doi: 10.1212/WNL.0b013e31823dc535.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/22156988/pubmed\" target=\"_blank\" id=\"22156988\">22156988</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19602654\"></a>Shefrin AE, Goldman RD. Use of dexamethasone and prednisone in acute asthma exacerbations in pediatric patients. <i>Can Fam Physician</i>. 2009;55(7):704-706.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/19602654/pubmed\" target=\"_blank\" id=\"19602654\">19602654</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Singh M, Sharma CS, Rautela RS, Taneja A. Intravenous dexamethasone causes perineal pain and pruritus. J Anesthe Clinic Res. 2011;4:273. doi:10.4172/2155-6148.1000273. http://www.omicsonline.org/intravenous-dexamethasone-causes-perineal-pain-and-pruritus-2155-6148.1000273.pdf </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22802322\"></a>Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. <i>J Clin Oncol</i>. 2012;30(24):2946-2955. doi: 10.1200/JCO.2011.39.6820.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/22802322/pubmed\" target=\"_blank\" id=\"22802322\">22802322</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sparrow A and Geelhoed G, &quot;Prednisolone Versus Dexamethasone in Croup: A Randomised Equivalence Trial,&quot; <i>Arch Dis Child</i>, 2006, 91(7):580-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/16624882/pubmed\" target=\"_blank\" id=\"16624882\">16624882</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sprung CL, Annane D, Keh D, et al, &ldquo;Hydrocortisone Therapy for Patients With Septic Shock,&rdquo; <i>N Engl J Med</i>, 2008, 358(2):111-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/18184957/pubmed\" target=\"_blank\" id=\"18184957\">18184957</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    TaperDex 6-Day (dexamethasone) [prescribing information]. Ridgeland, MS: Xspire Pharma; January 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    TaperDex 12-Day (dexamethasone) [prescribing information]. Ridgeland, MS: Xspire Pharma; January 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"1993963\"></a>Tellez DW, Galvis AG, Storgion SA, et al. Dexamethasone in the Prevention of Postextubation Stridor in Children. <i>J Pediatr.</i> 1991;118(2):289-294.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/1993963/pubmed\" target=\"_blank\" id=\"1993963\">1993963</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    T&oacute;th GG, Kloosterman C, Uges DR, Jonkman MF. Pharmacokinetics of high-dose oral and intravenous dexamethasone. <i>Ther Drug Monit</i>. 1999;21(5):532-535.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/10519450/pubmed\" target=\"_blank\" id=\"10519450\">10519450</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trissel LA and Zhang Y, &ldquo;Compatibility and Stability of Aloxi (Palonosetron Hydrochloride) Admixed With Dexamethasone Sodium Phosphate,&rdquo; <i>Intl J Pharm Compounding</i>, 2004, 8(5):398-403.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15494903\"></a>Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice Guidelines for the Management of Bacterial Meningitis. <i>Clin Infect Dis.</i> 2004;39(9):1267-1284.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/15494903/pubmed\" target=\"_blank\" id=\"15494903\">15494903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wald ER, Kaplan SL, and Mason, EO Jr, &ldquo;Dexamethasone Therapy for Children With Bacterial Meningitis,&rdquo; <i>Pediatrics</i>, 1995, 95(1):21-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/7770303/pubmed\" target=\"_blank\" id=\"7770303\">7770303</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wei Y, Ji XB, Wang YW, et al. High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. <i>Blood</i>. 2016 Jan 21;127(3):296-302.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/26480931/pubmed\" target=\"_blank\" id=\"26480931\">26480931</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-systemic-drug-information/abstract-text/17555487/pubmed\" target=\"_blank\" id=\"17555487\">17555487</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9100 Version 273.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F8015648\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F8015649\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F8016759\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F8015752\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F8015751\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F8015753\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F8015754\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15827036\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F8016329\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F8015651\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F8016306\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F8015652\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475108\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F8015647\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F8015706\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F8015703\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F8015704\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F8015710\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F8015711\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F8015698\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F8015699\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F8015702\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F8015756\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F8016312\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F8015721\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F8015724\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F8016331\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961968\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9100|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=dexamethasone-systemic-patient-drug-information\" class=\"drug drug_patient\">Dexamethasone (systemic): Patient drug information \t</a></li><li><a href=\"topic.htm?path=dexamethasone-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">Dexamethasone (systemic): Pediatric drug information</a></li></ul></div></div>","javascript":null}